Theralase® Extends Warrants

Toronto, ON – Theralase® Technologies Inc. (TSXV:TLT)(OTCQB:TLTFF), a clinical-stage pharmaceutical company, announced the extension of the expiry date for 10,000,000 share purchase warrants. Initially set to expire on September 22, 2024, these warrants will now be valid until September 22, 2027.

The warrants, issued on September 22, 2022, as part of a private placement, are exercisable at $0.35 per share. All other terms and conditions remain unchanged. The extension is pending final approval from the TSX Venture Exchange.

Theralase specializes in the development of light, radiation, sound, and drug-activated small molecules aimed at treating cancers, bacteria, and viruses safely and effectively. For more information, visit www.theralase.com or www.sedarplus.ca.